Business Wire

Simpson Thacher Adds Leading Antitrust and Competition Lawyer Antonio Bavasso

15.12.2020 11:00:00 EET | Business Wire | Press release

Share

Simpson Thacher & Bartlett LLP announced today that Antonio Bavasso will join the Firm’s London office, where he will be a Partner in the Antitrust and Trade Regulation Practice.

Antonio is widely recognized as a leading lawyer in antitrust and regulation, with more than twenty years of experience in some of the most high-profile and precedent-setting merger, behavioural and litigation cases internationally. He advises clients across a broad range of industries, including the technology, media and telecom sectors, in a wide variety of matters before the European Commission, the United Kingdom Competition and Markets Authority and other global competition authorities.

“Antonio has extensive experience that is relevant to our clients, having advised on the antitrust aspects of some of the most high-profile transactions in recent years. That experience will further enhance our ability to provide clients operating across Europe with top-tier advice in both tackling complex transactions and in navigating the enforcement landscape,” said Bill Dougherty, Chairman of Simpson Thacher’s Executive Committee. “We are very pleased to welcome him to the Firm.”

Simpson Thacher’s Antitrust and Trade Regulation Practice advises companies across every major industry on their global antitrust and competition needs, as well as on regulatory issues impacting their interests and operations around the world. The Firm counsels clients on the full array of antitrust enforcement, litigation and investigation issues—from cartel and other anticompetitive activity to litigation of private antitrust actions—as well as regulatory and compliance matters related to cross-border activities such as trade regulation and economic sanctions.

“Antonio is known throughout the market for his superb judgment and ability to provide clients with insightful and practical advice on high-profile, cross-border transactions, as well as in complex antitrust litigation and enforcement matters. This diversity of experience makes him a natural fit for Simpson Thacher and a wonderful addition to both our global M&A and Antitrust and Trade Regulation Practices, and sets the stage for the further expansion of our European antitrust and competition practice,” said David Vann, Head of Antitrust for Europe and Asia at Simpson Thacher.

“Given the sophistication and versatility of his experience, Antonio will deliver tremendous value to our clients and is an excellent addition to our outstanding group of lawyers in London,” added Jason Glover, Managing Partner of the Firm’s London Office. “Along with our recent promotion of Étienne Renaudeau to Partner, we expect David, Antonio and Étienne to spearhead the future growth of our European antitrust practice.”

Antonio joins the Firm from Allen & Overy LLP, where he was Co-Head of the Global Antitrust Practice and Co-Head of the Telecoms, Media and Technology Practice. He is both U.K. and Italy-qualified. He received his J.D., magna cum laude, from the University of Florence and a Ph.D. from University College London, where he is a visiting professor and Co-Founder and Co-Director of the Jevons Institute for Competition Law and Economics. Antonio is also a non-governmental adviser on unilateral practices and merger control for the International Competition Network of competition authorities.

ABOUT SIMPSON THACHER

Simpson Thacher & Bartlett LLP (www.simpsonthacher.com) is one of the world’s leading international law firms. The Firm was established in 1884 and has more than 1,000 lawyers. Headquartered in New York with offices in Beijing, Hong Kong, Houston, London, Los Angeles, Palo Alto, São Paulo, Tokyo and Washington, D.C., the Firm provides coordinated legal advice and transactional capability to clients around the globe.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media:
Caroline Fatchett
Simpson Thacher
Assoc. Director, Communications
Caroline.Fatchett@stblaw.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 11:11:00 EEST | Press release

Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye